Long-term raloxifene for postmenopausal osteoporosis

References

• Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine. Defining the ‘S’ in SERMs. Science 2002;295:2380-1
   Google Scholar
• Evista USPI. Available at: http://pi.lilly.com/us/evista-pi.pdf [Last accessed 22 February 2011]
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999;282:637-45. Erratum in: JAMA 1999;282:2124
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk–benefit profile for raloxifene: 4-year data from the Muliple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004;19:1270-5
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on the risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97. Erratum in JAMA 1999;282:2124
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34. Erratum in Breast Cancer Res Treat 2001;67:191
   PubMed Web of Science ®Google Scholar
• Guidelines for the preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, MD: FDA Division of Metabolic and Endocrine Drug Products, 1994. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM131206.pdf [Last accessed 22 February 2011]
   Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
   PubMed Web of Science ®Google Scholar
• Recker RR, Kimmel DB, Parfitt AM, et al. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 1988;3:133-44
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10
   PubMed Web of Science ®Google Scholar
• Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-8
   PubMed Web of Science ®Google Scholar
• Eastell R, Rogers A, Ni X, et al. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporos Int 2010; 22:1927-34
   PubMed Web of Science ®Google Scholar
• Michalská D, Stepan JJ, Basson BR, et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006;91:870-7
   PubMed Web of Science ®Google Scholar
• Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92
   PubMed Web of Science ®Google Scholar
• Ott SM, Oleksik A, Lu Y, et al. Bone histomophometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 2002;17:341-8
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-22
   PubMed Web of Science ®Google Scholar
• Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202
   PubMed Web of Science ®Google Scholar
• Boivin G, Lips P, Ott SM, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 2003;88:4199-205
   PubMed Web of Science ®Google Scholar
• Byrjalsen I, Leeming DJ, Qvist P, et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008;19:339-48
   PubMed Web of Science ®Google Scholar
• Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44
   PubMed Web of Science ®Google Scholar